Welcome to Bausch Health, Canada

As a company dedicated to innovation and advancement of global health, Bausch Health is constantly building on our commitment to help Canadians and people around the world live longer, healthier and more productive lives, through initiatives that often go beyond health care.

  • Reaching out from our Canadian headquarters to 100 countries around the world
  • Proudly collaborating with patient communities, physicians, universities, hospitals, and charitable organizations to improve lives with our health care products

Read More About Who We Are»

Latest News
November, 2024

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada’s Drug Agency and Quebec’s INESSS

September, 2024

Health Canada Approves PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

May, 2024

Bausch Health, Canada Inc. announces additional public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults

April, 2024

Acne vulgaris treatment PrARAZLOTM (tazarotene lotion, 0.045%) now available to patients through British Columbia PharmaCare public drug plan

April, 2024

Bausch Health, Canada Inc. announces first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to help address the unmet need for the treatment of mild to moderate distal ulcerative colitis in adults

December, 2023

DUOBRIITM lotion to treat moderate to severe plaque psoriasis now available through Quebec’s public drug plan

Our mission: Improving people’s lives with our health care products

Learn more about our products.

See Our Canadian Product List»

NYSE:BHC

$8.190

TSX:BHC

$11.48